Identification

Name
Escitalopram
Accession Number
DB01175  (APRD00683)
Type
Small Molecule
Groups
Approved, Investigational
Description

Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Escitalopram may be used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD).

Structure
Thumb
Synonyms
  • (+)-Citalopram
  • (S)-Citalopram
  • Escitalopram
  • Escitalopramum
  • S-(+)-Citalopram
  • S(+)-Citalopram
Product Ingredients
IngredientUNIICASInChI Key
Escitalopram oxalate5U85DBW7LO219861-08-2KTGRHKOEFSJQNS-BDQAORGHSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act EscitalopramTablet5 mgOralTevaNot applicableNot applicableCanada
Act EscitalopramTablet20 mgOralTeva2014-09-10Not applicableCanada
Act EscitalopramTablet10 mgOralTeva2014-09-10Not applicableCanada
Act Escitalopram ODTTablet, orally disintegrating20 mgOralActavis Pharma Company2016-08-17Not applicableCanada
Act Escitalopram ODTTablet, orally disintegrating10 mgOralActavis Pharma Company2016-08-17Not applicableCanada
Cipralex -5mgTablet5 mgOralLundbeck Inc.Not applicableNot applicableCanada
Cipralex -10mgTablet10 mgOralLundbeck Inc.2005-02-14Not applicableCanada
Cipralex -15mgTablet15 mgOralLundbeck Inc.Not applicableNot applicableCanada
Cipralex -20mgTablet20 mgOralLundbeck Inc.2005-02-14Not applicableCanada
Cipralex MeltzTablet, orally disintegrating10 mgOralLundbeck Inc.2012-10-04Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-escitalopramTablet10 mgOralAccord Healthcare Limited2016-06-10Not applicableCanada
Ach-escitalopramTablet20 mgOralAccord Healthcare Limited2016-06-10Not applicableCanada
Apo-escitalopramTablet20 mgOralApotex Corporation2014-09-10Not applicableCanada
Apo-escitalopramTablet10 mgOralApotex Corporation2014-09-10Not applicableCanada
Auro-escitalopramTablet20 mgOralAuro Pharma Inc2014-09-10Not applicableCanada
Auro-escitalopramTablet15 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-escitalopramTablet10 mgOralAuro Pharma Inc2014-09-10Not applicableCanada
Auro-escitalopramTablet5 mgOralAuro Pharma IncNot applicableNot applicableCanada
EscitalopramTablet, film coated10 mg/1OralHikma Pharmaceutical2012-09-11Not applicableUs
EscitalopramTablet5 mg/1OralCamber Pharmaceuticals2012-09-11Not applicableUs
International/Other Brands
Cipralex / Esertia
Categories
UNII
4O4S742ANY
CAS number
128196-01-0
Weight
Average: 324.3919
Monoisotopic: 324.163791509
Chemical Formula
C20H21FN2O
InChI Key
WSEQXVZVJXJVFP-FQEVSTJZSA-N
InChI
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1
IUPAC Name
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
SMILES
CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1

Pharmacology

Indication

Labeled indications include major depressive disorder (MDD) and generalized anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-associated agitation in nonpsychotic patients.

Associated Conditions
Pharmacodynamics

Escitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that escitalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase.

Mechanism of action

The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Escitalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
USodium-dependent dopamine transporter
inhibitor
Human
USodium-dependent noradrenaline transporter
inhibitor
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
UHistamine H1 receptor
antagonist
Human
Absorption

The absolute bioavailability of citalopram is about 80% relative to an intravenous dose.

Volume of distribution
  • 12 L/kg
Protein binding

~56%

Metabolism

Mainly hepatic. Escitalopram undergoes N-demethylation to S-demethylcitalopram (S-DCT) and S-didemethylcitalopram (S-DDCT). CYP3A4 and CYP2C19 are the enzymes responsible for this N-demethylation reaction.

Route of elimination

Following oral administrations of escitalopram, the fraction of drug recovered in the urine as escitalopram and S-demethylcitalopram (S-DCT) is about 8% and 10%, respectively. The oral clearance of escitalopram is 600 mL/min, with approximately 7% of that due to renal clearance. Escitalopram is metabolized to S-DCT and S-didemethylcitalopram (S-DDCT).

Half life

27-32 hours

Clearance
  • oral cl=600 mL/min [Following oral administrations]
Toxicity

Signs of overdose include convulsions, coma, dizziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including QT prolongation).

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Escitalopram Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Sodium-dependent serotonin transporter---(A;A)A alleleADR Directly StudiedThe presence of this polymorphism in SLC6A4 may potentially be associated with increased risk of adverse events from escitalopram.Details
Cytochrome P450 2C19CYP2C19*2Not Available681G>AEffect Directly StudiedThe presence of this polymorphism in CYP2C19 is associated with poor metabolism of escitalopram.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>AEffect Directly StudiedThe presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of escitalopram.Details
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Escitalopram.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Escitalopram.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Escitalopram.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Escitalopram.Experimental, Illicit
4-MethoxyamphetamineEscitalopram may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Escitalopram.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Escitalopram.Experimental
AbirateroneThe serum concentration of Escitalopram can be increased when it is combined with Abiraterone.Approved
AcarboseEscitalopram may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Escitalopram.Approved, Investigational
AceclofenacEscitalopram may increase the antiplatelet activities of Aceclofenac.Approved, Investigational
AcenocoumarolEscitalopram may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineEscitalopram may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Escitalopram.Approved
AcetaminophenEscitalopram may increase the antiplatelet activities of Acetaminophen.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Acetophenazine.Approved
Acetyl sulfisoxazoleThe metabolism of Escitalopram can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidEscitalopram may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Escitalopram.Investigational
AdrafinilEscitalopram may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineEscitalopram may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Escitalopram.Approved, Investigational
AlaproclateEscitalopram may increase the serotonergic activities of Alaproclate.Experimental
AlbiglutideEscitalopram may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Escitalopram.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Escitalopram.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Escitalopram.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Escitalopram.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Escitalopram.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Escitalopram.Approved, Investigational
AlogliptinEscitalopram may increase the hypoglycemic activities of Alogliptin.Approved
AlosetronAlosetron may increase the serotonergic activities of Escitalopram.Approved, Withdrawn
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Escitalopram.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Escitalopram.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Escitalopram.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Escitalopram.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Escitalopram.Approved
AmibegronEscitalopram may decrease the vasoconstricting activities of Amibegron.Investigational
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Escitalopram.Illicit, Withdrawn
Aminosalicylic AcidEscitalopram may increase the antiplatelet activities of Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Amiodarone is combined with Escitalopram.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Escitalopram.Approved, Investigational
AmitrazEscitalopram may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Escitalopram.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Escitalopram.Approved, Investigational
AmlodipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Escitalopram.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Escitalopram.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Escitalopram.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Amphetamine.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Escitalopram is combined with Amrinone.Approved
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Escitalopram.Approved
AnisodamineEscitalopram may decrease the vasoconstricting activities of Anisodamine.Investigational
AntipyrineEscitalopram may increase the antiplatelet activities of Antipyrine.Approved, Investigational
AntrafenineEscitalopram may increase the antiplatelet activities of Antrafenine.Approved
ApalutamideThe serum concentration of Escitalopram can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
ApraclonidineEscitalopram may decrease the vasoconstricting activities of Apraclonidine.Approved
AprepitantThe serum concentration of Escitalopram can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Aranidipine.Approved, Investigational
ArbutamineEscitalopram may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
AripiprazoleAripiprazole may increase the antihypertensive activities of Escitalopram.Approved, Investigational
ArmodafinilThe metabolism of Escitalopram can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Escitalopram.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Escitalopram.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Escitalopram.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Asenapine.Approved
AtazanavirThe metabolism of Escitalopram can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Escitalopram.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Escitalopram.Approved
AvanafilAvanafil may increase the hypotensive activities of Escitalopram.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Escitalopram.Investigational, Vet Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Escitalopram.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Escitalopram is combined with Azimilide.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Escitalopram.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Escitalopram.Approved
BalsalazideEscitalopram may increase the antiplatelet activities of Balsalazide.Approved, Investigational
BambuterolEscitalopram may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Escitalopram.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Barnidipine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Escitalopram.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Escitalopram.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Escitalopram is combined with Bencyclane.Experimental
BendroflumethiazideEscitalopram may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenidipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Benidipine.Approved, Investigational
BenmoxinThe risk or severity of adverse effects can be increased when Escitalopram is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Escitalopram.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Escitalopram.Approved, Investigational
BenzphetamineEscitalopram may decrease the vasoconstricting activities of Benzphetamine.Approved, Illicit
BenzthiazideEscitalopram may increase the hyponatremic activities of Benzthiazide.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Escitalopram.Approved
Benzylpenicilloyl PolylysineEscitalopram may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of hypotension can be increased when Escitalopram is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Escitalopram.Approved, Investigational
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Escitalopram.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Escitalopram.Approved, Investigational
BevantololBevantolol may increase the antihypertensive activities of Escitalopram.Approved
BezitramideBezitramide may increase the serotonergic activities of Escitalopram.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Escitalopram is combined with Bifeprunox.Investigational
BioallethrinThe risk or severity of hypotension can be increased when Escitalopram is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Escitalopram.Approved
BitolterolEscitalopram may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Escitalopram.Investigational
BoceprevirThe serum concentration of Escitalopram can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Escitalopram.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
BosentanThe serum concentration of Escitalopram can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleEscitalopram may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Escitalopram.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Escitalopram.Approved, Illicit, Investigational
BromfenacEscitalopram may increase the antiplatelet activities of Bromfenac.Approved
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Escitalopram.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Escitalopram.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Escitalopram.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Escitalopram.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Escitalopram.Investigational
BufexamacEscitalopram may increase the antiplatelet activities of Bufexamac.Approved, Experimental
BufuralolBufuralol may increase the orthostatic hypotensive activities of Escitalopram.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Escitalopram.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Escitalopram.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Escitalopram.Approved
BuprenorphineBuprenorphine may increase the serotonergic activities of Escitalopram.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Escitalopram can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
BuspironeBuspirone may increase the serotonergic activities of Escitalopram.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Escitalopram.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Escitalopram.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Escitalopram.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Escitalopram.Approved, Withdrawn
ButaperazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Escitalopram.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Escitalopram.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Escitalopram.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Escitalopram.Approved
CanagliflozinEscitalopram may increase the hypoglycemic activities of Canagliflozin.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Escitalopram.Investigational
CapsaicinEscitalopram may increase the antiplatelet activities of Capsaicin.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Escitalopram.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Escitalopram.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Escitalopram is combined with Carboxyamidotriazole.Investigational
CarfentanilCarfentanil may increase the serotonergic activities of Escitalopram.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Cariprazine.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Escitalopram.Approved
CaroverineThe risk or severity of hypotension can be increased when Escitalopram is combined with Caroverine.Experimental
CaroxazoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Caroxazone.Withdrawn
CarprofenEscitalopram may increase the antiplatelet activities of Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Escitalopram.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Escitalopram.Approved, Investigational
CelecoxibEscitalopram may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Escitalopram.Approved, Investigational
CeritinibThe serum concentration of Escitalopram can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Escitalopram.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Escitalopram.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Escitalopram can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Escitalopram.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Escitalopram.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Escitalopram.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational, Vet Approved
ChlorothiazideEscitalopram may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Escitalopram.Approved
ChlorphenesinEscitalopram may increase the antiplatelet activities of Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphentermineChlorphentermine may decrease the sedative activities of Escitalopram.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Escitalopram.Experimental
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational, Vet Approved
ChlorpropamideEscitalopram may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Escitalopram.Approved, Investigational, Withdrawn
ChlorthalidoneEscitalopram may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Escitalopram.Approved
CholecalciferolThe metabolism of Escitalopram can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateEscitalopram may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved
CilnidipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Cilnidipine.Approved, Investigational
CimetidineThe serum concentration of Escitalopram can be increased when it is combined with Cimetidine.Approved, Investigational
CimicoxibEscitalopram may increase the antiplatelet activities of Cimicoxib.Investigational
CinacalcetThe metabolism of Escitalopram can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Escitalopram.Approved, Vet Approved
CinnarizineThe risk or severity of hypotension can be increased when Escitalopram is combined with Cinnarizine.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
CirazolineEscitalopram may decrease the vasoconstricting activities of Cirazoline.Experimental
CisaprideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Escitalopram.Approved, Investigational, Withdrawn
CisplatinEscitalopram may increase the antiplatelet activities of Cisplatin.Approved
CitalopramThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Escitalopram.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Escitalopram.Approved
ClemastineThe metabolism of Escitalopram can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolEscitalopram may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Escitalopram.Approved
ClobazamThe metabolism of Escitalopram can be decreased when combined with Clobazam.Approved, Illicit
Clodronic AcidEscitalopram may increase the antiplatelet activities of Clodronic Acid.Approved, Investigational, Vet Approved
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Escitalopram.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Escitalopram.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Escitalopram.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Escitalopram.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Escitalopram.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Escitalopram.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Escitalopram.Approved, Illicit
ClorindioneEscitalopram may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Escitalopram.Experimental
ClotrimazoleThe metabolism of Escitalopram can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Escitalopram.Approved
CobicistatThe serum concentration of Escitalopram can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Escitalopram can be decreased when combined with Cocaine.Approved, Illicit
CodeineCodeine may increase the serotonergic activities of Escitalopram.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Escitalopram.Approved, Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Escitalopram.Approved
CurcuminThe metabolism of Escitalopram can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Cyamemazine.Approved
CyclandelateThe risk or severity of hypotension can be increased when Escitalopram is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Escitalopram.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Escitalopram.Approved
CyclopenthiazideEscitalopram may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Escitalopram.Experimental
CyclosporineThe metabolism of Escitalopram can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Escitalopram can be decreased when used in combination with Cyproheptadine.Approved
DabrafenibThe serum concentration of Escitalopram can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Escitalopram.Approved, Investigational
DapagliflozinEscitalopram may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleDapiprazole may increase the antihypertensive activities of Escitalopram.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Escitalopram.Investigational
DarifenacinThe metabolism of Escitalopram can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Darodipine.Experimental
DarunavirThe serum concentration of Escitalopram can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Escitalopram can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Escitalopram can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Escitalopram.Approved
DelamanidEscitalopram may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelavirdineThe metabolism of Escitalopram can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Escitalopram.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Escitalopram.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Escitalopram.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Escitalopram.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin.Approved
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Escitalopram.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Escitalopram.Vet Approved
DeutetrabenazineEscitalopram may increase the QTc-prolonging activities of Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Escitalopram.Approved
DexibuprofenEscitalopram may increase the antiplatelet activities of Dexibuprofen.Approved, Investigational
DexketoprofenEscitalopram may increase the antiplatelet activities of Dexketoprofen.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Escitalopram.Approved, Vet Approved
DextroamphetamineEscitalopram may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanEscitalopram may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Escitalopram.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Escitalopram.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the serotonergic activities of Escitalopram.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Escitalopram.Approved, Illicit, Investigational, Vet Approved
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Escitalopram.Experimental
DiclofenacEscitalopram may increase the antiplatelet activities of Diclofenac.Approved, Vet Approved
DicoumarolEscitalopram may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Escitalopram.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Escitalopram.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Escitalopram.Approved, Illicit
DiflunisalEscitalopram may increase the antiplatelet activities of Diflunisal.Approved, Investigational
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Escitalopram.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Escitalopram.Approved, Investigational
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Escitalopram.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Escitalopram.Experimental, Illicit
DiltiazemThe metabolism of Escitalopram can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Escitalopram.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Escitalopram.Approved, Withdrawn
DiphenadioneEscitalopram may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Escitalopram.Approved, Illicit
DipivefrinEscitalopram may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Escitalopram.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Escitalopram.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Escitalopram.Experimental
DL-MethylephedrineEscitalopram may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineEscitalopram may decrease the vasoconstricting activities of Dobutamine.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Dofetilide is combined with Escitalopram.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Domperidone.Approved, Investigational, Vet Approved
DopexamineEscitalopram may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Escitalopram.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Escitalopram.Approved
DotarizineThe risk or severity of hypotension can be increased when Escitalopram is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Escitalopram.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Escitalopram.Approved, Investigational
DoxofyllineEscitalopram may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxycyclineThe metabolism of Escitalopram can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Escitalopram.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Escitalopram.Experimental
DronedaroneThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
DrospirenoneEscitalopram may increase the antiplatelet activities of Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Escitalopram.Experimental, Illicit
DroxicamEscitalopram may increase the antiplatelet activities of Droxicam.Withdrawn
DroxidopaEscitalopram may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DulaglutideEscitalopram may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Escitalopram.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Escitalopram.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Escitalopram.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Escitalopram.Investigational
EfavirenzThe metabolism of Escitalopram can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Escitalopram.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Escitalopram.Investigational
EmpagliflozinEscitalopram may increase the hypoglycemic activities of Empagliflozin.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Escitalopram.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Escitalopram.Approved, Investigational
EnzalutamideThe serum concentration of Escitalopram can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Escitalopram.Experimental
EperisoneThe risk or severity of hypotension can be increased when Escitalopram is combined with Eperisone.Approved, Investigational
EphedraEscitalopram may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineEscitalopram may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineEscitalopram may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineEscitalopram may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
EpitizideEscitalopram may increase the hyponatremic activities of Epitizide.Experimental
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Escitalopram.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Escitalopram.Approved
EribulinEribulin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Escitalopram.Experimental
Eslicarbazepine acetateThe metabolism of Escitalopram can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Escitalopram.Approved
EsomeprazoleThe metabolism of Escitalopram can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Escitalopram.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Escitalopram.Approved, Investigational
EtafedrineEscitalopram may decrease the vasoconstricting activities of Etafedrine.Approved
EtanerceptEscitalopram may increase the antiplatelet activities of Etanercept.Approved, Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Escitalopram.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Escitalopram.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Escitalopram.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Escitalopram.Approved
Ethyl biscoumacetateEscitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Escitalopram.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Escitalopram.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Escitalopram.Approved, Illicit
EthylmorphineEthylmorphine may increase the serotonergic activities of Escitalopram.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Escitalopram.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Escitalopram.Investigational, Withdrawn
EtilefrineEscitalopram may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Escitalopram.Approved
EtodolacEscitalopram may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Escitalopram.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Escitalopram.Withdrawn
EtoricoxibEscitalopram may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Escitalopram.Illicit, Vet Approved
EtravirineThe metabolism of Escitalopram can be decreased when combined with Etravirine.Approved
ExenatideEscitalopram may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Escitalopram.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Escitalopram.Approved
FelodipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Escitalopram.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Escitalopram is combined with Fendiline.Withdrawn
FenfluramineEscitalopram may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoprofenEscitalopram may increase the antiplatelet activities of Fenoprofen.Approved
FenoterolEscitalopram may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Escitalopram.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Escitalopram.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Escitalopram.Approved, Investigational
FingolimodFingolimod may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Fish oilEscitalopram may increase the antiplatelet activities of Fish oil.Approved, Nutraceutical
FlecainideFlecainide may increase the QTc-prolonging activities of Escitalopram.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Escitalopram.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Escitalopram.Experimental
FluconazoleThe metabolism of Escitalopram can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Escitalopram.Approved, Illicit
FluindioneEscitalopram may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Escitalopram.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Escitalopram.Approved, Illicit
FluoxetineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Escitalopram.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Escitalopram.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Escitalopram.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Escitalopram.Approved, Illicit, Investigational
FlurbiprofenEscitalopram may increase the antiplatelet activities of Flurbiprofen.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Escitalopram.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Escitalopram.Approved
FluvoxamineThe metabolism of Escitalopram can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
FosamprenavirThe metabolism of Escitalopram can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Escitalopram can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Escitalopram.Approved
FosphenytoinThe metabolism of Escitalopram can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Escitalopram.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Escitalopram.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Escitalopram.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Escitalopram.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Escitalopram can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Escitalopram.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Escitalopram.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Escitalopram.Approved
GallopamilThe risk or severity of hypotension can be increased when Escitalopram is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Escitalopram.Approved, Illicit, Investigational
GemfibrozilThe metabolism of Escitalopram can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
GepefrineGepefrine may decrease the sedative activities of Escitalopram.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Escitalopram.Investigational
GinsengEscitalopram may increase the antiplatelet activities of Ginseng.Approved, Investigational, Nutraceutical
GliclazideEscitalopram may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideEscitalopram may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideEscitalopram may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Escitalopram.Approved, Illicit
GlyburideEscitalopram may increase the hypoglycemic activities of Glyburide.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Escitalopram.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
GuanabenzEscitalopram may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Escitalopram.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Escitalopram.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Escitalopram.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Escitalopram.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Escitalopram.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Escitalopram.Approved
HexoprenalineEscitalopram may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineEscitalopram may decrease the vasoconstricting activities of Higenamine.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Escitalopram.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Escitalopram.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Hydracarbazine.Experimental
HydrochlorothiazideEscitalopram may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the serotonergic activities of Escitalopram.Approved, Illicit
HydroflumethiazideEscitalopram may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneHydromorphone may increase the serotonergic activities of Escitalopram.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Escitalopram.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Escitalopram.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
IbuprofenEscitalopram may increase the antiplatelet activities of Ibuprofen.Approved
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Escitalopram.Approved
IcosapentEscitalopram may increase the antiplatelet activities of Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Escitalopram can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Iloperidone.Approved
ImatinibThe metabolism of Escitalopram can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Escitalopram.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Escitalopram.Approved
IndalpineIndalpine may increase the serotonergic activities of Escitalopram.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Escitalopram.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Escitalopram.Withdrawn
IndinavirThe metabolism of Escitalopram can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Escitalopram.Investigational
IndomethacinEscitalopram may increase the antiplatelet activities of Indomethacin.Approved, Investigational
IndoraminIndoramin may increase the antihypertensive activities of Escitalopram.Withdrawn
Insulin AspartEscitalopram may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirEscitalopram may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineEscitalopram may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineEscitalopram may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanEscitalopram may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproEscitalopram may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Escitalopram.Approved, Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Escitalopram.Approved
Ioflupane I-123Escitalopram may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Escitalopram.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Iproclozide.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Escitalopram.Withdrawn
IsavuconazoleThe serum concentration of Escitalopram can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Escitalopram can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Escitalopram can be increased when used in combination with Isocarboxazid.Approved
IsoetarineEscitalopram may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
IsomethepteneEscitalopram may decrease the vasoconstricting activities of Isometheptene.Approved
IsoniazidThe metabolism of Escitalopram can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineEscitalopram may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineEscitalopram may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
ItraconazoleThe metabolism of Escitalopram can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineEscitalopram may increase the QTc-prolonging activities of Ivabradine.Approved
IvacaftorThe serum concentration of Escitalopram can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Escitalopram.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Escitalopram.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Escitalopram.Approved, Investigational
KetoconazoleThe metabolism of Escitalopram can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenEscitalopram may increase the antiplatelet activities of Ketoprofen.Approved, Vet Approved
KetorolacEscitalopram may increase the antiplatelet activities of Ketorolac.Approved
L-TryptophanL-Tryptophan may increase the serotonergic activities of Escitalopram.Approved, Nutraceutical, Withdrawn
LabetalolLabetalol may increase the antihypertensive activities of Escitalopram.Approved
LacidipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Escitalopram.Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Escitalopram.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Escitalopram.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Escitalopram.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Escitalopram.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Escitalopram.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Escitalopram.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Escitalopram.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Escitalopram.Approved, Investigational
LevorphanolLevorphanol may increase the serotonergic activities of Escitalopram.Approved
LevosalbutamolEscitalopram may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Escitalopram.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Escitalopram.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Escitalopram is combined with Lidoflazine.Experimental
LinezolidLinezolid may increase the serotonergic activities of Escitalopram.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Escitalopram.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Escitalopram.Approved
LiraglutideEscitalopram may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineEscitalopram may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the serotonergic activities of Escitalopram.Approved
LobeglitazoneThe metabolism of Escitalopram can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilLofentanil may increase the serotonergic activities of Escitalopram.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Escitalopram.Experimental
LofexidineEscitalopram may decrease the vasoconstricting activities of Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Escitalopram is combined with Loperamide.Approved
LopinavirThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Escitalopram.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Escitalopram.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Escitalopram.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Escitalopram is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Escitalopram.Approved
LornoxicamEscitalopram may increase the antiplatelet activities of Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Escitalopram can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Escitalopram can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Escitalopram.Approved
LuliconazoleThe serum concentration of Escitalopram can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Escitalopram can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Lumefantrine.Approved
LumiracoxibEscitalopram may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Escitalopram.Approved, Investigational
MacimorelinEscitalopram may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
Magnesium salicylateEscitalopram may increase the antiplatelet activities of Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of adverse effects can be increased when Magnesium sulfate is combined with Escitalopram.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Escitalopram can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Escitalopram.Experimental
MecaserminEscitalopram may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Escitalopram.Approved
Meclofenamic acidEscitalopram may increase the antiplatelet activities of Meclofenamic acid.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Escitalopram.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Escitalopram.Vet Approved
Mefenamic acidEscitalopram may increase the antiplatelet activities of Mefenamic acid.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Escitalopram.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Escitalopram.Experimental, Investigational
MeloxicamEscitalopram may increase the antiplatelet activities of Meloxicam.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Escitalopram.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Escitalopram is combined with Menthol.Approved
MephedroneMephedrone may decrease the sedative activities of Escitalopram.Investigational
MephentermineEscitalopram may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Escitalopram.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Escitalopram.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Escitalopram.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Escitalopram.Experimental
MesalazineEscitalopram may increase the antiplatelet activities of Mesalazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Escitalopram.Approved, Investigational
MetaraminolEscitalopram may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Escitalopram.Approved
MetforminEscitalopram may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Escitalopram.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Escitalopram.Approved, Illicit
MethamphetamineEscitalopram may decrease the vasoconstricting activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Escitalopram.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Escitalopram.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Escitalopram.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Escitalopram.Approved
MethotrimeprazineMethotrimeprazine may increase the antihypertensive activities of Escitalopram.Approved, Investigational
MethoxamineEscitalopram may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Escitalopram.Approved, Investigational, Vet Approved
MethoxyphenamineEscitalopram may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Escitalopram.Approved
MethyclothiazideEscitalopram may increase the hyponatremic activities of Methyclothiazide.Approved
MethyldopaEscitalopram may decrease the vasoconstricting activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Escitalopram.Experimental
Methylene blueEscitalopram may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Escitalopram.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Escitalopram.Approved, Investigational
MetolazoneEscitalopram may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Escitalopram.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Escitalopram.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Escitalopram.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Escitalopram.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Escitalopram is combined with Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Escitalopram.Approved, Illicit
MidodrineEscitalopram may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineMidomafetamine may decrease the sedative activities of Escitalopram.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Escitalopram can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneEscitalopram may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MiglitolEscitalopram may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranMilnacipran may increase the serotonergic activities of Escitalopram.Approved, Investigational
MinaprineMinaprine may increase the serotonergic activities of Escitalopram.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Escitalopram.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Escitalopram.Investigational
MirtazapineMirtazapine may increase the QTc-prolonging activities of Escitalopram.Approved
MitotaneThe serum concentration of Escitalopram can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may decrease the sedative activities of Escitalopram.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Escitalopram can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Escitalopram.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Escitalopram.Approved
MoperoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Escitalopram.Approved, Investigational, Withdrawn
MorniflumateEscitalopram may increase the antiplatelet activities of Morniflumate.Approved
MorphineMorphine may increase the serotonergic activities of Escitalopram.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Mosapramine.Experimental
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
MoxonidineEscitalopram may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Escitalopram.Approved, Investigational
NabumetoneEscitalopram may increase the antiplatelet activities of Nabumetone.Approved
NadololNadolol may increase the orthostatic hypotensive activities of Escitalopram.Approved
NaftopidilThe risk or severity of hypotension can be increased when Escitalopram is combined with Naftopidil.Investigational
NalbuphineNalbuphine may increase the serotonergic activities of Escitalopram.Approved
NaphazolineEscitalopram may decrease the vasoconstricting activities of Naphazoline.Approved
NaproxenEscitalopram may increase the antiplatelet activities of Naproxen.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Escitalopram.Approved, Investigational
NateglinideEscitalopram may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Escitalopram.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Escitalopram.Approved, Withdrawn
NelfinavirThe metabolism of Escitalopram can be decreased when combined with Nelfinavir.Approved
NepafenacEscitalopram may increase the antiplatelet activities of Nepafenac.Approved, Investigational
NetupitantThe serum concentration of Escitalopram can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Escitalopram can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Escitalopram.Withdrawn
NicardipineNicardipine may increase the antihypertensive activities of Escitalopram.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Escitalopram.Approved, Investigational
NicomorphineNicomorphine may increase the serotonergic activities of Escitalopram.Experimental
NifedipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Nifedipine.Approved
Niflumic AcidEscitalopram may increase the antiplatelet activities of Niflumic Acid.Approved
NiguldipineEscitalopram may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Nilvadipine.Approved, Investigational
NimesulideEscitalopram may increase the antiplatelet activities of Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Escitalopram.Approved
NitrendipineThe risk or severity of hypotension can be increased when Escitalopram is combined with Nitrendipine.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Escitalopram.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Escitalopram.Approved
NorepinephrineEscitalopram may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineEscitalopram may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Escitalopram.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Escitalopram.Approved, Investigational
NormethadoneNormethadone may increase the serotonergic activities of Escitalopram.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Escitalopram.Approved
NylidrinEscitalopram may decrease the vasoconstricting activities of Nylidrin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Escitalopram is combined with Octamoxin.Withdrawn
OctopamineEscitalopram may decrease the vasoconstricting activities of Octopamine.Experimental
OctreotideOctreotide may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Escitalopram.Approved
OlanzapineOlanzapine may increase the antihypertensive activities of Escitalopram.Approved, Investigational
OlaparibThe metabolism of Escitalopram can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Escitalopram.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Escitalopram.Approved
OmeprazoleThe serum concentration of Escitalopram can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Escitalopram.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Escitalopram.Investigational
OpiumOpium may increase the serotonergic activities of Escitalopram.Approved, Illicit
OrciprenalineEscitalopram may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Escitalopram.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Escitalopram.Investigational
OsimertinibThe serum concentration of Escitalopram can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of hypotension can be increased when Escitalopram is combined with Otilonium.Experimental, Investigational
OxaprozinEscitalopram may increase the antiplatelet activities of Oxaprozin.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Escitalopram.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Escitalopram.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Escitalopram.Approved, Investigational
OxycodoneOxycodone may increase the serotonergic activities of Escitalopram.Approved, Illicit, Investigational
OxyfedrineEscitalopram may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineEscitalopram may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphoneOxymorphone may increase the serotonergic activities of Escitalopram.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Oxypertine.Experimental
OxytocinOxytocin may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
PalbociclibThe serum concentration of Escitalopram can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Escitalopram.Approved, Investigational
PanobinostatThe serum concentration of Escitalopram can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Escitalopram can be decreased when combined with Pantoprazole.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Escitalopram.Approved, Investigational
ParecoxibEscitalopram may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Escitalopram.Approved
ParoxetineThe metabolism of Escitalopram can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Escitalopram.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Escitalopram.Approved
Peginterferon alfa-2bThe serum concentration of Escitalopram can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Escitalopram.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Escitalopram.Experimental
PentamidinePentamidine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
PentazocinePentazocine may increase the serotonergic activities of Escitalopram.Approved, Vet Approved
PentobarbitalThe metabolism of Escitalopram can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Escitalopram.Approved, Investigational
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Escitalopram.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Escitalopram.Approved, Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Escitalopram.Approved
PergolideEscitalopram may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Escitalopram.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Escitalopram.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Escitalopram.Approved
PhenazocinePhenazocine may increase the serotonergic activities of Escitalopram.Experimental
PhendimetrazineEscitalopram may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Escitalopram.Experimental
PhenindioneEscitalopram may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Escitalopram can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidinePhenoperidine may increase the serotonergic activities of Escitalopram.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Escitalopram.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Escitalopram.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Phenoxypropazine.Withdrawn
PhenprocoumonEscitalopram may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenterminePhentermine may decrease the sedative activities of Escitalopram.Approved, Illicit
PhentolamineEscitalopram may increase the antihypertensive activities of Phentolamine.Approved
PhenylbutazoneEscitalopram may increase the antiplatelet activities of Phenylbutazone.Approved, Vet Approved
PhenylephrineEscitalopram may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineEscitalopram may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Escitalopram can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of QTc prolongation can be increased when Pimozide is combined with Escitalopram.Approved
PinaveriumThe risk or severity of hypotension can be increased when Escitalopram is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Escitalopram.Approved, Investigational
PioglitazoneEscitalopram may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Escitalopram.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pipotiazine.Approved, Investigational
PirbuterolEscitalopram may decrease the vasoconstricting activities of Pirbuterol.Approved
PiritramidePiritramide may increase the serotonergic activities of Escitalopram.Approved, Investigational
PirlindolePirlindole may increase the serotonergic activities of Escitalopram.Approved
PiroxicamEscitalopram may increase the antiplatelet activities of Piroxicam.Approved, Investigational
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Escitalopram.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pivhydrazine.Withdrawn
PizotifenEscitalopram may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Escitalopram.Experimental
PolythiazideEscitalopram may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Escitalopram.Approved
PosaconazoleThe metabolism of Escitalopram can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Escitalopram.Approved
PramlintideEscitalopram may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Escitalopram.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Escitalopram.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Escitalopram.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Escitalopram.Approved, Illicit, Investigational
PrenalterolEscitalopram may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Escitalopram is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Escitalopram.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Escitalopram.Approved
PrimidoneThe metabolism of Escitalopram can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Procainamide is combined with Escitalopram.Approved
ProcaineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Procarbazine.Approved, Investigational
ProcaterolEscitalopram may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Escitalopram.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
PropafenonePropafenone may increase the QTc-prolonging activities of Escitalopram.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Escitalopram.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Escitalopram.Approved, Vet Approved
PropericiazineEscitalopram may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Escitalopram.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Escitalopram.Vet Approved
PropiverineEscitalopram may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolPropofol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Escitalopram.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Escitalopram.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Escitalopram is combined with Prothipendyl.Investigational
ProtokylolEscitalopram may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Escitalopram.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Escitalopram.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Escitalopram.Investigational
PseudoephedrineEscitalopram may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Escitalopram.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Quetiapine.Approved
QuinethazoneEscitalopram may increase the hyponatremic activities of Quinethazone.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Escitalopram.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Escitalopram.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Escitalopram.Experimental
RacepinephrineEscitalopram may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Escitalopram.Investigational
RactopamineEscitalopram may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Escitalopram.Approved, Investigational
RanolazineRanolazine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Rasagiline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Escitalopram.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Escitalopram.Approved, Withdrawn
RepaglinideEscitalopram may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReproterolEscitalopram may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Escitalopram.Approved, Investigational
ResveratrolEscitalopram may increase the antiplatelet activities of Resveratrol.Approved, Experimental, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Escitalopram.Approved, Investigational
RifabutinThe metabolism of Escitalopram can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Escitalopram can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Escitalopram can be increased when combined with Rifapentine.Approved, Investigational
RilmenidineEscitalopram may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Escitalopram.Approved
RimiterolEscitalopram may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneThe metabolism of Risperidone can be decreased when combined with Escitalopram.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Escitalopram.Investigational
RitobegronEscitalopram may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineEscitalopram may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe metabolism of Escitalopram can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Escitalopram.Approved
RofecoxibEscitalopram may increase the antiplatelet activities of Rofecoxib.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Escitalopram can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Escitalopram.Vet Approved
RopiniroleThe metabolism of Escitalopram can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Escitalopram.Approved
RosiglitazoneEscitalopram may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RucaparibThe metabolism of Escitalopram can be decreased when combined with Rucaparib.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Safrazine.Withdrawn
SalbutamolSalbutamol may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
Salicylic acidEscitalopram may increase the antiplatelet activities of Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Escitalopram.Approved
SalsalateEscitalopram may increase the antiplatelet activities of Salsalate.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
SarilumabThe therapeutic efficacy of Escitalopram can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinEscitalopram may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Escitalopram.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Escitalopram.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Selegiline.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Escitalopram is combined with Seletracetam.Investigational
SeliciclibEscitalopram may increase the antiplatelet activities of Seliciclib.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Escitalopram.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Escitalopram.Approved, Investigational, Withdrawn
SertralineSertraline may increase the serotonergic activities of Escitalopram.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Escitalopram.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Escitalopram.Approved
SiltuximabThe serum concentration of Escitalopram can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Escitalopram.Approved
SitagliptinEscitalopram may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Escitalopram.Approved
SolabegronEscitalopram may decrease the vasoconstricting activities of Solabegron.Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Escitalopram.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Escitalopram.Approved
St. John's WortThe serum concentration of Escitalopram can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Escitalopram can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the serotonergic activities of Escitalopram.Approved, Investigational
SulfadiazineEscitalopram may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Escitalopram.Approved
SulfasalazineEscitalopram may increase the antiplatelet activities of Sulfasalazine.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
SulindacEscitalopram may increase the antiplatelet activities of Sulindac.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Escitalopram.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Escitalopram.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Escitalopram.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
SuprofenEscitalopram may increase the antiplatelet activities of Suprofen.Approved, Withdrawn
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Escitalopram.Approved, Investigational
SynephrineEscitalopram may decrease the vasoconstricting activities of Synephrine.Experimental
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Escitalopram.Approved, Investigational
TadalafilTadalafil may increase the hypotensive activities of Escitalopram.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Escitalopram.Investigational
TalniflumateEscitalopram may increase the antiplatelet activities of Talniflumate.Approved
TamoxifenTamoxifen may increase the QTc-prolonging activities of Escitalopram.Approved
TamsulosinTamsulosin may increase the antihypertensive activities of Escitalopram.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Escitalopram.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Escitalopram is combined with Tapentadol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Escitalopram.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Escitalopram.Approved
TelaprevirThe serum concentration of Escitalopram can be decreased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Escitalopram.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Escitalopram.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Escitalopram.Approved, Investigational
TenoxicamEscitalopram may increase the antiplatelet activities of Tenoxicam.Approved
TerazosinTerazosin may increase the antihypertensive activities of Escitalopram.Approved
TerbinafineThe metabolism of Escitalopram can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Escitalopram.Approved
TerodilineThe risk or severity of hypotension can be increased when Escitalopram is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Escitalopram.Experimental
TetrabenazineThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Escitalopram.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Escitalopram.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Escitalopram.Investigational
TetryzolineEscitalopram may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Escitalopram.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Escitalopram.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Escitalopram.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Escitalopram.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Escitalopram.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Escitalopram.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Escitalopram is combined with Thiopropazate.Experimental
ThioproperazineEscitalopram may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Escitalopram.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Escitalopram.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Escitalopram.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Escitalopram.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Escitalopram.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Escitalopram.Approved, Investigational
Tiaprofenic acidEscitalopram may increase the antiplatelet activities of Tiaprofenic acid.Approved
TiclopidineThe metabolism of Escitalopram can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Escitalopram.Vet Approved
TilidineTilidine may increase the serotonergic activities of Escitalopram.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Escitalopram.Approved
TioclomarolEscitalopram may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe metabolism of Escitalopram can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
TocilizumabThe serum concentration of Escitalopram can be decreased when it is combined with Tocilizumab.Approved
TolazamideEscitalopram may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Escitalopram.Approved, Vet Approved
TolbutamideEscitalopram may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Escitalopram.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Escitalopram is combined with Tolfenamic Acid.Approved, Investigational
TolmetinEscitalopram may increase the antiplatelet activities of Tolmetin.Approved
ToloxatoneToloxatone may increase the serotonergic activities of Escitalopram.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
TopiramateThe metabolism of Escitalopram can be decreased when combined with Topiramate.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Escitalopram.Approved, Investigational
TramadolEscitalopram may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Escitalopram is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Tranylcypromine.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Escitalopram.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
TretoquinolEscitalopram may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamcinoloneEscitalopram may increase the antiplatelet activities of Triamcinolone.Approved, Vet Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Escitalopram.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Escitalopram.Vet Approved
TrichlormethiazideEscitalopram may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Escitalopram.Approved
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Escitalopram.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Escitalopram.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Escitalopram.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Escitalopram.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Escitalopram is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Escitalopram is combined with Trimethadione.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Escitalopram.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Escitalopram.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
Trolamine salicylateEscitalopram may increase the antiplatelet activities of Trolamine salicylate.Approved
TropisetronTropisetron may increase the serotonergic activities of Escitalopram.Approved, Investigational
TulobuterolEscitalopram may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Escitalopram.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Escitalopram.Investigational
ValdecoxibEscitalopram may increase the antiplatelet activities of Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Escitalopram.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Escitalopram.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Escitalopram.Approved
VenlafaxineVenlafaxine may increase the serotonergic activities of Escitalopram.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Escitalopram.Experimental
VerapamilEscitalopram may increase the antihypertensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Escitalopram.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Escitalopram.Approved
VilazodoneEscitalopram may increase the serotonergic activities of Vilazodone.Approved
VinpocetineThe risk or severity of hypotension can be increased when Escitalopram is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Escitalopram.Experimental
VoriconazoleThe metabolism of Escitalopram can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
VortioxetineEscitalopram may increase the serotonergic activities of Vortioxetine.Approved, Investigational
WarfarinEscitalopram may increase the anticoagulant activities of Warfarin.Approved
WIN 55212-2The risk or severity of hypotension can be increased when Escitalopram is combined with WIN 55212-2.Experimental
XamoterolEscitalopram may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Escitalopram.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Escitalopram.Vet Approved
XylometazolineEscitalopram may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Escitalopram.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Escitalopram.Approved
ZimelidineEscitalopram may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Escitalopram.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Escitalopram.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Escitalopram.Approved, Investigational
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Escitalopram.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Escitalopram.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Escitalopram.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Escitalopram.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Escitalopram can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Robert Dancer, "Escitalopram hydrobromide and a method for the preparation thereof." U.S. Patent US20040167209, issued August 26, 2004.

US20040167209
General References
  1. Moore N, Verdoux H, Fantino B: Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol. 2005 May;20(3):131-7. [PubMed:15812262]
  2. Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M: A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin. 2006 Jul;22(7):1331-41. [PubMed:16834832]
  3. Bielski RJ, Ventura D, Chang CC: A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004 Sep;65(9):1190-6. [PubMed:15367045]
  4. Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM: Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin. 2007 Feb;23(2):401-16. [PubMed:17288694]
  5. Chen F, Larsen MB, Sanchez C, Wiborg O: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005 Mar;15(2):193-8. [PubMed:15695064]
External Links
Human Metabolome Database
HMDB0005028
PubChem Compound
146570
PubChem Substance
46507040
ChemSpider
129277
BindingDB
50302225
ChEBI
36791
ChEMBL
CHEMBL1508
Therapeutic Targets Database
DAP000741
PharmGKB
PA10074
HET
68P
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Escitalopram
ATC Codes
N06AB10 — Escitalopram
AHFS Codes
  • 28:16.04.20 — Selective-serotonin Reuptake Inhibitors
PDB Entries
5i71 / 5i73 / 5i75
FDA label
Download (1.09 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Unknown StatusTreatmentPremature Ejaculation1
1Active Not RecruitingTreatmentSpinal Cord Injuries (SCI)2
1CompletedNot AvailableCocaine Abuse / Dependence, Cocaine / Substance Abuse1
1CompletedNot AvailableHealthy Volunteers4
1CompletedBasic ScienceDepression1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceHepatitis C Infection1
1CompletedDiagnosticHealthy Volunteers1
1CompletedOtherAnxiety Disorders1
1CompletedTreatmentHealthy Men1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentHepatitis C Viral Infection1
1CompletedTreatmentHepatitis C Virus (HCV)1
1CompletedTreatmentMajor Depressive Disorder (MDD)2
1CompletedTreatmentPatients With Chronic Stroke1
1RecruitingOtherMajor Depressive Disorder (MDD)1
1RecruitingPreventionAlzheimer's Disease (AD)1
1TerminatedTreatmentDepression, Bipolar1
1Unknown StatusTreatmentAnxiety Disorders1
1, 2CompletedTreatmentMajor Depressive Disorder (MDD)1
2Active Not RecruitingTreatmentEnd Stage Renal Disease (ESRD)1
2Active Not RecruitingTreatmentMajor Depressive Disorder (MDD)1
2CompletedPreventionChronic Hepatitis C Virus (HCV) Infection / Major Depressive Disorder (MDD)1
2CompletedTreatmentAnxiety Disorders / Depression1
2CompletedTreatmentBipolar Disorder (BD)1
2CompletedTreatmentBorderline Personality Disorder (BPD)1
2CompletedTreatmentDepression1
2CompletedTreatmentMajor Depressive Disorder (MDD)8
2CompletedTreatmentMajor Depressive Disorder (MDD) / Other Psychiatric Disorders / Tbi1
2CompletedTreatmentMajor Depressive Disorder (MDD) / Sleeplessness1
2CompletedTreatmentObsessive Compulsive Disorder (OCD)1
2CompletedTreatmentSocial Anxiety Disorder (SAD)1
2Not Yet RecruitingTreatmentMajor Depressive Disorder (MDD)1
2RecruitingOtherDepression1
2RecruitingSupportive CareStrokes1
2RecruitingTreatmentIrritable Bowel Syndrome-Constipation / Rectal Hypersensitivity1
2RecruitingTreatmentMale Infertility / Sperm DNA Fragmentation1
2TerminatedTreatmentAddictions1
2TerminatedTreatmentMajor Depressive Disorder (MDD)1
2Unknown StatusTreatmentPosttraumatic Stress Disorders1
2WithdrawnTreatmentPosttraumatic Stress Disorders1
2, 3CompletedBasic ScienceDependence, Cocaine1
2, 3CompletedPreventionHepatitis C Viral Infection1
2, 3CompletedTreatmentAlzheimer's Disease (AD) / Major Depressive Disorder (MDD) / Mild Cognitive Impairment (MCI)1
2, 3CompletedTreatmentDepression1
2, 3CompletedTreatmentDepression / Parkinson's Disease (PD)1
2, 3CompletedTreatmentDepression / Suicide, Attempted1
2, 3CompletedTreatmentDyspepsia and Other Specified Disorders of Function of Stomach1
2, 3CompletedTreatmentGeneralized Anxiety Disorder (GAD)1
2, 3CompletedTreatmentPhobic Disorders1
2, 3Not Yet RecruitingSupportive CareDepression / GBM1
2, 3Not Yet RecruitingTreatmentDepression1
2, 3RecruitingTreatmentMajor Depressive Disorder (MDD)1
2, 3TerminatedTreatmentUnipolar Depression1
3CompletedDiagnosticMajor Depressive Disorder (MDD)1
3CompletedPreventionDepression1
3CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS) / Disseminated Sclerosis / Major Depressive Disorder (MDD)1
3CompletedTreatmentAnxiety Disorders / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentAnxiety Disorders / Somatoform Disorders1
3CompletedTreatmentAtypical Depression1
3CompletedTreatmentDepression1
3CompletedTreatmentDepression / Depressive Disorders / Major Depressive Disorder (MDD)1
3CompletedTreatmentDepression / Major Depressive Disorder (MDD)1
3CompletedTreatmentDepression / Opiate Dependence1
3CompletedTreatmentDepressive Disorder, Treatment-Resistant / Major depressive disorder, recurrent episode2
3CompletedTreatmentDepressive Disorders1
3CompletedTreatmentENT Cancer1
3CompletedTreatmentGeneralized Anxiety1
3CompletedTreatmentMajor Depressive Disorder (MDD)10
3CompletedTreatmentMajor Depressive Disorder (MDD) / Major Depressive Disorder, Recurrent, Unspecified / Major Depressive Disorder, Single Episode, Unspecified1
3CompletedTreatmentMajor depressive disorder, recurrent episode3
3CompletedTreatmentNight Eating Syndrome1
3CompletedTreatmentObsessive-Compulsive Disorder (OCD)1
3CompletedTreatmentPulmonary Hypertension (PH)1
3CompletedTreatmentSchizophrenic Disorders1
3CompletedTreatmentTreatment Outcomes1
3Not Yet RecruitingTreatmentDepressive Disorder, Treatment-Resistant1
3RecruitingTreatmentBipolar I Disorder1
3RecruitingTreatmentDementias1
3RecruitingTreatmentDepression / Feeling Anxious / Indigestion1
3RecruitingTreatmentDepression / MCI1
3RecruitingTreatmentFibromyalgia1
3TerminatedPreventionAnxiety Disorders1
3TerminatedSupportive CareColorectal Cancers / Depression / Esophageal Cancers / Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer / Lung Cancers / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Tiredness1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentDepression With Prominent Agitation1
3TerminatedTreatmentDepressive Disorders1
3TerminatedTreatmentMajor Depressive Disorder (MDD)3
3TerminatedTreatmentMajor Depressive Disorder (MDD) / Sleeplessness1
3Unknown StatusPreventionCerebrovascular Accidents / Depression1
3Unknown StatusTreatmentCarcinoma NOS1
3Unknown StatusTreatmentChronic Depression1
3Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
3WithdrawnTreatmentChronic Obstructive Pulmonary Disease (COPD) / Feeling Anxious1
4Active Not RecruitingTreatmentAnxiety Disorders / Major Depressive Disorder (MDD)1
4Active Not RecruitingTreatmentMajor Depressive Disorder (MDD)2
4CompletedNot AvailableAsthma Bronchial / Major Depressive Disorder (MDD)1
4CompletedNot AvailableDepression1
4CompletedNot AvailableDysphoria1
4CompletedNot AvailableSchizophrenic Disorders1
4CompletedBasic ScienceDepression2
4CompletedBasic ScienceFear Conditioning1
4CompletedBasic SciencePanic Disorders1
4CompletedDiagnosticAnxiety Disorders / Major Depressive Disorder (MDD)1
4CompletedDiagnosticHealthy Volunteers1
4CompletedHealth Services ResearchMajor Depressive Disorder (MDD)1
4CompletedOtherHealthy Controls / Major Depressive Disorder (MDD)1
4CompletedPreventionDepression3
4CompletedScreeningIrritable Bowel Syndrome (IBS)1
4CompletedTreatmentAcute Agitation / Alzheimer's Disease (AD) / Psychosis1
4CompletedTreatmentAlcohol Abuse / Alcohol Dependence / Major Depressive Disorder (MDD)1
4CompletedTreatmentAlcoholism / Depression1
4CompletedTreatmentAlzheimer's Disease (AD)1
4CompletedTreatmentAlzheimer's Disease (AD) / Psychomotor Agitation1
4CompletedTreatmentAntidepressant Activity in Healthy Volunteers1
4CompletedTreatmentAnxiety Disorders / Generalized Anxiety Disorder (GAD)1
4CompletedTreatmentCoronary Artery Disease1
4CompletedTreatmentCoronary Heart Disease (CHD) / Depressive Disorders1
4CompletedTreatmentDementias2
4CompletedTreatmentDementias / Depression1
4CompletedTreatmentDepression7
4CompletedTreatmentDepression / Diabetes Mellitus (DM)1
4CompletedTreatmentDepression / Dysthymic Disorder / Major Depressive Disorder (MDD)1
4CompletedTreatmentDysthymic Disorder1
4CompletedTreatmentDysthymic Disorder / Major Depressive Disorder (MDD)2
4CompletedTreatmentGeneralized Anxiety Disorder (GAD)2
4CompletedTreatmentHealthy Volunteers2
4CompletedTreatmentImpulse Control Disorders1
4CompletedTreatmentInternet Addiction1
4CompletedTreatmentIrritable Bowel Syndrome (IBS) / Panic Disorders1
4CompletedTreatmentMajor Depressive Disorder (MDD)19
4CompletedTreatmentMajor Depressive Disorder (MDD) / Temporal Lobe Epilepsy1
4CompletedTreatmentModerate or Severe Major Depressive Disorder / Severe Asthma1
4CompletedTreatmentMyocardial Ischemia1
4CompletedTreatmentObsessive Compulsive Disorder (OCD)2
4CompletedTreatmentOveractive Bladder1
4CompletedTreatmentPTSD1
4CompletedTreatmentPain / Polyneuropathies1
4CompletedTreatmentPolycystic Ovaries Syndrome1
4CompletedTreatmentPostoperative pain1
4CompletedTreatmentPostpartum Depression1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentSleep disorders and disturbances1
4CompletedTreatmentSleeplessness1
4CompletedTreatmentSocial Anxiety Disorder (SAD)1
4Enrolling by InvitationTreatmentDepression / Epilepsies / Feeling Anxious1
4Not Yet RecruitingBasic ScienceNeuronal Plasticity / Ssri1
4Not Yet RecruitingTreatmentDiagnosis and Treatment of Depression1
4RecruitingNot AvailableDepressive Disorders / Lactation1
4RecruitingBasic ScienceDepression1
4RecruitingBasic ScienceMajor Depressive Disorder (MDD)2
4RecruitingDiagnosticAsthma Bronchial / Asthma: [Nos] or [Attack] / Major Depressive Disorder (MDD)1
4RecruitingHealth Services ResearchMajor Depressive Disorder (MDD)1
4RecruitingPreventionMajor Depressive Disorder (MDD)1
4RecruitingTreatmentAnxiety Disorders / Fear of open spaces / Generalized Anxiety Disorder (GAD) / Panic Disorders / Social Anxiety Disorder (SAD)1
4RecruitingTreatmentDepression2
4RecruitingTreatmentDepression / Hard of Hearing1
4RecruitingTreatmentDepressive Disorder, NOS / Dysthymic Disorder / Major Depressive Disorder (MDD)1
4RecruitingTreatmentMajor Depressive Disorder (MDD)4
4SuspendedTreatmentDepression1
4TerminatedTreatmentBipolar Disorder (BD)1
4TerminatedTreatmentChronic Rhinosinusitis / Depression / Facial Pain Disorder1
4TerminatedTreatmentDepression2
4TerminatedTreatmentDepression / Human Immunodeficiency Virus (HIV)1
4TerminatedTreatmentEpilepsies / Major Depressive Disorder (MDD)1
4TerminatedTreatmentMajor Depressive Disorder (MDD)2
4TerminatedTreatmentMajor Depressive Disorder With Psychotic Features1
4TerminatedTreatmentPerimenopausal Depression1
4TerminatedTreatmentPremenstrual Syndrome1
4Unknown StatusNot AvailableMajor Depressive Disorder (MDD)1
4Unknown StatusDiagnosticSchizophrenic Disorders1
4Unknown StatusPreventionDepression2
4Unknown StatusTreatmentAbdominal Pain (AP) / Major Depressive Disorder (MDD) / Pain1
4Unknown StatusTreatmentDepression2
4Unknown StatusTreatmentDepression / Dysthymic Disorder1
4Unknown StatusTreatmentDepressive Syndrome1
4Unknown StatusTreatmentDiabetes Mellitus (DM) / Major Depressive Disorder (MDD)1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)4
4Unknown StatusTreatmentMajor Depressive Disorder (MDD) / Sleeplessness1
4Unknown StatusTreatmentObsessive Compulsive Disorder (OCD)1
4Unknown StatusTreatmentObsessive Compulsive Disorder (OCD) / Schizophrenic Disorders1
4Unknown StatusTreatmentStrokes1
4WithdrawnTreatmentDepression / Epilepsies / Feeling Anxious1
4WithdrawnTreatmentDepression / Low Back Pain (LBP)1
4WithdrawnTreatmentStrokes1
Not AvailableActive Not RecruitingNot AvailableCancer, Breast / Depression / Menopausal Hot Flushes / Psychosocial Effects of Cancer and Its Treatment1
Not AvailableActive Not RecruitingNot AvailableMajor Depressive Disorder (MDD)2
Not AvailableActive Not RecruitingDiagnosticGeneralized Anxiety Disorder (GAD) / Separation Anxiety Disorder / Social Phobia1
Not AvailableActive Not RecruitingTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Depression / Human Immunodeficiency Virus (HIV)1
Not AvailableActive Not RecruitingTreatmentAdverse Reaction to Drug / Continuous Antidepressant Abuse / Depression1
Not AvailableCompletedNot AvailableAcute Kidney Injury (AKI) / Depression1
Not AvailableCompletedNot AvailableDepression2
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableMajor Depressive Disorder (MDD)1
Not AvailableCompletedNot AvailableObsessive Compulsive Disorder (OCD)1
Not AvailableCompletedBasic ScienceAnxiety Disorders / Cardiovascular Disease (CVD) / Insulin Resistance / Low Birth Weight / Melancholic Depression / Type 2 Diabetes Mellitus1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic ScienceMajor Depressive Disorder (MDD)1
Not AvailableCompletedBasic ScienceSpinal Cord Injuries (SCI)1
Not AvailableCompletedDiagnosticHealthy Volunteers1
Not AvailableCompletedHealth Services ResearchDepression / Depression Secondary to Other Disease1
Not AvailableCompletedHealth Services ResearchMajor Depressive Disorder (MDD)1
Not AvailableCompletedOtherMajor Depressive Disorder (MDD)1
Not AvailableCompletedPreventionPost-Traumatic Stress Disorder (PTSD)2
Not AvailableCompletedTreatmentAlzheimer's Disease (AD)1
Not AvailableCompletedTreatmentChronic Posttraumatic Stress Disorder1
Not AvailableCompletedTreatmentDepression5
Not AvailableCompletedTreatmentGeneralized Anxiety Disorder (GAD)2
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)4
Not AvailableCompletedTreatmentMenopausal Hot Flushes / Menopause / Vasomotor Symptoms1
Not AvailableCompletedTreatmentNight Eating Syndrome1
Not AvailableCompletedTreatmentPostpartum Depression2
Not AvailableCompletedTreatmentStress Disorders, Post Traumatic1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableNot Yet RecruitingTreatmentSocial Anxiety Disorder (SAD)1
Not AvailableRecruitingNot AvailableObesity, Morbid1
Not AvailableRecruitingBasic ScienceAdolescents / Depression1
Not AvailableRecruitingOtherObsessive-Compulsive Disorder (OCD)1
Not AvailableRecruitingTreatmentBipolar Disorder (BD) / Depression / Feeling Anxious1
Not AvailableRecruitingTreatmentCardiovascular Disease (CVD) / Feeling Anxious1
Not AvailableRecruitingTreatmentDepression1
Not AvailableRecruitingTreatmentDepression / Inflammatory Reaction1
Not AvailableRecruitingTreatmentFeeling Anxious1
Not AvailableRecruitingTreatmentMajor Depressive Disorder (MDD)1
Not AvailableSuspendedBasic SciencePharmacokinetics1
Not AvailableTerminatedTreatmentPanic Disorders / Sleeplessness1
Not AvailableUnknown StatusNot AvailableDissociative Disorders1
Not AvailableUnknown StatusNot AvailableMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusNot AvailablePrurigo Nodularis1
Not AvailableUnknown StatusBasic ScienceDepression1
Not AvailableUnknown StatusTreatmentAssisted Reproductive Technology therapy / Depression / Feeling Anxious1
Not AvailableUnknown StatusTreatmentBorderline Personality Disorder (BPD)1
Not AvailableUnknown StatusTreatmentDepression1
Not AvailableUnknown StatusTreatmentDepression / Perimenopause1
Not AvailableUnknown StatusTreatmentMajor Depressive Disorder (MDD)2
Not AvailableUnknown StatusTreatmentMajor Depressive Disorder (MDD) / Sleeplessness1
Not AvailableUnknown StatusTreatmentMarijuana Dependence1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Bryant Ranch Prepack
  • Cardinal Health
  • Direct Pharmaceuticals Inc.
  • Diversified Healthcare Services Inc.
  • Forest Laboratories Inc.
  • Forest Pharmaceuticals
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • Lake Erie Medical and Surgical Supply
  • Lundbeck Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Prepak Systems Inc.
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
TabletOral5 mg
TabletOral10 mg
TabletOral15 mg
TabletOral20 mg
Tablet, orally disintegratingOral10 mg
Tablet, orally disintegratingOral20 mg
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
Tablet, coatedOral20 mg/1
Tablet, film coatedOral5 mg/1
SolutionOral5 mg/5mL
Tablet, film coatedOral10 mg/21
Tablet, film coatedOral20 mg/21
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Prices
Unit descriptionCostUnit
Lexapro 20 mg tablet3.71USD tablet
Lexapro 10 mg tablet3.55USD tablet
Lexapro 5 mg tablet3.4USD tablet
Lexapro 5 mg/5ml Solution0.72USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
USRE34712No1994-09-142011-09-14Us
CA2373757No2010-01-052020-07-07Canada
CA1339452No1997-09-092014-09-09Canada
US7420069Yes2003-02-122023-02-12Us
US6916941Yes2003-02-122023-02-12Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00588 mg/mLALOGPS
logP3.58ALOGPS
logP3.76ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)9.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area36.26 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.02 m3·mol-1ChemAxon
Polarizability35.21 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9729
Caco-2 permeable+0.6099
P-glycoprotein substrateSubstrate0.7597
P-glycoprotein inhibitor INon-inhibitor0.6361
P-glycoprotein inhibitor IIInhibitor0.9789
Renal organic cation transporterInhibitor0.6993
CYP450 2C9 substrateNon-substrate0.8401
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.5054
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5223
Ames testNon AMES toxic0.7602
CarcinogenicityNon-carcinogens0.7452
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9054 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7735
hERG inhibition (predictor II)Inhibitor0.8994
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-1497000000-a840cd3176ff240d74f6

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylbutylamines
Direct Parent
Phenylbutylamines
Alternative Parents
Isocoumarans / Fluorobenzenes / Aralkylamines / Aryl fluorides / Trialkylamines / Oxacyclic compounds / Nitriles / Dialkyl ethers / Organopnictogen compounds / Organofluorides
show 1 more
Substituents
Phenylbutylamine / Isocoumaran / Fluorobenzene / Halobenzene / Aralkylamine / Aryl halide / Aryl fluoride / Tertiary amine / Tertiary aliphatic amine / Oxacycle
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile (CHEBI:36791)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Owens MJ, Knight DL, Nemeroff CB: Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001 Sep 1;50(5):345-50. [PubMed:11543737]
  2. Owens JM, Knight DL, Nemeroff CB: [Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine]. Encephale. 2002 Jul-Aug;28(4):350-5. [PubMed:12232544]
  3. Burke WJ: Escitalopram. Expert Opin Investig Drugs. 2002 Oct;11(10):1477-86. [PubMed:12387707]
  4. Waugh J, Goa KL: Escitalopram : a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003;17(5):343-62. [PubMed:12665392]
  5. Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O: Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 2003 Jun;167(4):353-62. Epub 2003 Apr 26. [PubMed:12719960]
  6. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059]
  7. Fabre V, Hamon M: [Mechanisms of action of antidepressants: new data from Escitalopram]. Encephale. 2003 May-Jun;29(3 Pt 1):259-65. [PubMed:12876551]
  8. Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, Egebjerg J, Sanchez C: An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett. 2009 Oct 25;462(3):207-12. doi: 10.1016/j.neulet.2009.07.030. Epub 2009 Jul 16. [PubMed:19616061]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059]
  2. Fabre V, Hamon M: [Mechanisms of action of antidepressants: new data from Escitalopram]. Encephale. 2003 May-Jun;29(3 Pt 1):259-65. [PubMed:12876551]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059]
  2. Fabre V, Hamon M: [Mechanisms of action of antidepressants: new data from Escitalopram]. Encephale. 2003 May-Jun;29(3 Pt 1):259-65. [PubMed:12876551]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on June 18, 2018 06:30